This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.
Subject has biopsy-proven papillary or follicular thyroid cancer
Subject is clinically indicated for 123I-SPECT/CT total body iodine (TBI) scan
Subject agrees to undergo 18F-TFB PET/CT scan following TBI scan
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Contrast-enhanced CT within 4 last weeks
Amiodarone within last 4 months
Ingested iodine, kelp tablets, Lugols iodine, or potassium iodide (SSKI) within 2 weeks
Unable to lie flat, still or tolerate a PET scan